Indications
Open Access TIMES Journals
Login
Register
Login
Register
Indications
Oncology · Hematology
Cardiovascular
Diabetes + Endocrinology
Pneumology
Ophthalmology
Gynecology · Urology
Dermatology · Immunology · Rheumatology
Neurology · Psychiatry
Gastroenterology
Infectiology · Anesthesiology · Pain
Primary Care
Open Access TIMES Journals
Oncology · Hematology
Cardiovascular
Diabetes + Endocrinology
Pneumology
Ophthalmology
Gynecology · Urology
Dermatology · Immunology · Rheumatology
Neurology · Psychiatry
Gastroenterology
Infectiology · Anesthesiology · Pain
Primary Care
Gynecology · Urology
Case Reports
Expert Opinions
Webinar
Faculty
Homepage
>
Gynecology · Urology
>
Articles
Baldness and Risk of Prostate Cancer in the Health Professionals Follow-Up Study
Uro-Oncology
Share:
Related content
Further Publications Urology
Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study
Prostate Cancer Prostatic Dis
Liu AQ, Remmers S, Lau SY, Yip SY, Leung CH, Mak CW, Yee CH, Teoh JY, Hou SM, Roobol M, Ng CF, Chiu PK
doi: 10.1038/s41391-021-00444-y
Uro-Oncology
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer
BJU Int.
Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ
doi: 10.1111/bju.13676.
Uro-Oncology
Risk of dementia following androgen deprivation therapy for treatment of prostate cancer
Prostate Cancer Prostatic Dis.
Krasnova A, Epstein M, Marchese M, Dickerman BA, Cole AP, Lipsitz SR, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Mucci LA, Sun M, Trinh QD
doi: 10.1038/s41391-019-0189-3.
Uro-Oncology
Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study
Prostate Cancer Prostatic Dis.
Beckmann K, Garmo H, Lindahl B, Holmberg L, Stattin P, Adolfsson J, Cruickshank JK, Van Hemelrijck M
doi: 10.1038/s41391-020-0220-8.
Uro-Oncology
Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study
Eur Urol.
Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, Pettersson A
doi: 10.1016/j.eururo.2019.09.027.
Uro-Oncology
Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study
Prostate.
Lundgren PO, Kjellman A, Norming U, Gustafsson O
doi: 10.1002/pros.23991.
Uro-Oncology
Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Eur Urol.
Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK
doi: 10.1016/j.eururo.2020.02.009.
Uro-Oncology
Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis
Prostate Cancer Prostatic Dis.
Cui H, Wang Y, Li F, He G, Jiang Z, Gang X, Wang G
doi: 10.1038/s41391-020-00267-3.
Uro-Oncology
Association between metformin medication, genetic variation and prostate cancer risk
Prostate Cancer Prostatic Dis.
Lee MJ, Jayalath VH, Xu W, Lu L, Freedland SJ, Fleshner NE, Kulkarni GS, Finelli A, van der Kwast TH, Hamilton RJ
doi: 10.1038/s41391-020-0238-y.